Cancers 2010, 2(2), 955-969; doi:10.3390/cancers2020955
Review

Systemic Therapy of Non-Resectable Metastatic Melanoma

email, email and * email
Received: 8 March 2010; in revised form: 11 May 2010 / Accepted: 12 May 2010 / Published: 26 May 2010
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: In advanced metastatic melanoma (non-resectable stage III/IV), the prognosis still remains poor, with median survival times between six and twelve months. Systemic therapeutic approaches for metastatic melanoma include chemotherapy, immunotherapy, immunochemotherapy, small molecules and targeted therapy. In this review, we will focus on the various treatment modalities as well as new agents used for targeted therapy.
Keywords: melanoma; metastatic; chemotherapy; targeted therapy; small molecules
PDF Full-text Download PDF Full-Text [123 KB, uploaded 26 May 2010 10:03 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Orouji, A.; Goerdt, S.; Utikal, J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers 2010, 2, 955-969.

AMA Style

Orouji A, Goerdt S, Utikal J. Systemic Therapy of Non-Resectable Metastatic Melanoma. Cancers. 2010; 2(2):955-969.

Chicago/Turabian Style

Orouji, Azadeh; Goerdt, Sergij; Utikal, Jochen. 2010. "Systemic Therapy of Non-Resectable Metastatic Melanoma." Cancers 2, no. 2: 955-969.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert